📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
AstraZeneca Pharma India Seeks Approval for ₹3,900 Cr Related Party Transactions
AstraZeneca Pharma India Limited has issued a postal ballot notice to seek shareholder approval for material related party transactions (RPT) for the 2026-27 fiscal year. The company proposes transactions worth up to ₹2,400 crore with AstraZeneca UK Limited and up to ₹1,500 crore with AstraZeneca AB, Sweden. These transactions cover the purchase, transfer, or receipt of products, goods, and services essential for operations. The e-voting period is scheduled from February 28 to March 29, 2026, with results expected by March 31, 2026.
Key Highlights
Proposed transactions with AstraZeneca UK Limited capped at ₹2,400 crore for FY 2026-27.
Proposed transactions with AstraZeneca AB, Sweden capped at ₹1,500 crore for FY 2026-27.
Total value of material related party transactions under consideration is ₹3,900 crore.
E-voting period runs from February 28, 2026, to March 29, 2026.
Transactions include purchase of products, goods, materials, and reimbursement of transfer price or other obligations.
💼 Action for Investors
Investors should monitor the voting results and review the explanatory statement to ensure these large-scale transactions with parent entities are conducted at arm's length.
AstraZeneca India Q3 Revenue Surges 39% to INR 6,115.7 Mn; 8 New Regulatory Approvals Secured
AstraZeneca Pharma India reported a robust 39% YoY growth in total revenue for Q3 FY 2025-26, reaching INR 6,115.7 Mn. The growth was primarily driven by the Oncology segment, which contributed INR 4,395.9 Mn, and Biopharmaceuticals at INR 1,377.4 Mn. The company demonstrated strong pipeline execution with 8 new regulatory approvals over the past nine months, including key indications for Durvalumab and Osimertinib. Profit after tax for the quarter stood at INR 465.4 Mn, supported by consistent performance across all therapy areas.
Key Highlights
Total revenue for Q3 FY 2025-26 grew 39% YoY to INR 6,115.7 Mn.
Oncology segment contributed INR 4,395.9 Mn, representing approximately 72% of total quarterly revenue.
Secured 8 new regulatory approvals in 9 months, including treatments for endometrial cancer, MIBC, and rare diseases.
9-month (Apr-Dec '25) total revenue reached INR 16,969.7 Mn with a Profit Before Tax of INR 1,982.3 Mn.
Launched Eculizumab, the first anti-complement therapy in India for rare diseases aHUS and PNH.
💼 Action for Investors
Investors should note the strong revenue momentum and the significant expansion of the product portfolio through 8 new approvals. The company's focus on high-value oncology and rare disease segments suggests a positive outlook for long-term margin improvement.
AstraZeneca India Gets CDSCO Approval for Imfinzi in Endometrial Cancer Treatment
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab (Imfinzi) for an additional indication. The drug is now approved for first-line treatment of adults with primary advanced or recurrent endometrial cancer in combination with chemotherapy. This approval covers two dosage forms: 120 mg/2.4 mL and 500 mg/10 mL. This regulatory milestone allows the company to expand its oncology portfolio and address a critical therapeutic area in the Indian market.
Key Highlights
Received CDSCO permission to import and distribute Durvalumab (Brand: Imfinzi) for a new indication.
Approved for first-line treatment of primary advanced or recurrent endometrial cancer in combination with chemotherapy.
Available in two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL solution for infusion.
Includes maintenance treatment as monotherapy for mismatch repair deficient (dMMR) endometrial cancer.
💼 Action for Investors
This is a positive development that strengthens AstraZeneca's oncology pipeline in India. Investors should monitor the impact on specialty segment revenues in future earnings reports as the product is commercialized for this new indication.
AstraZeneca India Gets CDSCO Approval for Imfinzi to Treat Gastric Cancer
AstraZeneca Pharma India has received approval from the CDSCO to import and market Durvalumab (Imfinzi) for an additional indication in India. The drug is now permitted for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) in combination with FLOT chemotherapy. This approval covers two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL. This expansion of Imfinzi's therapeutic use is expected to enhance the company's oncology portfolio and addressable patient base.
Key Highlights
Received CDSCO permission to import and distribute Durvalumab (Imfinzi) for a new oncology indication.
Approved for treating adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Permission covers two specific formulations: 120 mg/2.4 mL and 500 mg/10 mL solutions for infusion.
The treatment protocol involves combination with FLOT chemotherapy followed by single-agent Durvalumab.
The approval paves the way for immediate marketing subject to any remaining statutory requirements.
💼 Action for Investors
Investors should monitor the commercial launch and uptake of Imfinzi for this new indication as it strengthens the company's high-margin oncology segment. This regulatory milestone is a positive driver for long-term revenue growth in the Indian market.
AstraZeneca Pharma India Appoints New Directors for Oncology and Institutional Business
AstraZeneca Pharma India has announced two key senior management appointments effective January 12, 2026, to strengthen its commercial leadership. Ms. Aditi Dayarus Mehta, with over 15 years of experience from Pfizer and BMS, joins as Director of the Oncology Business Unit. Mr. Nitin Bindal, an IIT Bombay and UCLA alumnus with 17 years of experience at BMS and J&J, has been appointed as Director for Institutional Business & Public Channels. These strategic hires from top-tier global competitors are aimed at driving growth in high-value therapeutic areas and expanding market access.
Key Highlights
Ms. Aditi Dayarus Mehta appointed as Director – Oncology Business Unit with 15+ years of leadership experience.
Mr. Nitin Bindal appointed as Director - Institutional Business & Public Channels with 17+ years of industry expertise.
Both appointments are effective from January 12, 2026, following Board and NRC approval.
New leaders bring specialized experience from global giants including Pfizer, Bristol Myers Squibb, and Johnson & Johnson.
💼 Action for Investors
Investors should view these high-caliber hires as a positive step toward strengthening the company's core oncology and institutional segments. Monitor the execution of new strategies in these divisions over the coming fiscal year.
AstraZeneca Pharma Receives CDSCO Approval for New Breast Cancer Drug Datverzo in India
AstraZeneca Pharma India has received permission from the CDSCO to import and market Datopotamab Deruxtecan (Brand name: Datverzo) 100 mg in India. The drug is indicated for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously received endocrine-based therapy and chemotherapy. This approval strengthens the company's oncology portfolio in the Indian market. Commercial marketing will commence following the receipt of any remaining statutory approvals.
Key Highlights
Received CDSCO approval for import and distribution of Datverzo (Datopotamab Deruxtecan) 100 mg
Indicated for metastatic HR-positive, HER2-negative breast cancer in adult patients
Targets patients who have failed prior endocrine-based therapy and chemotherapy
Marks a significant addition to AstraZeneca's specialty oncology pipeline in India
💼 Action for Investors
Investors should monitor the commercial launch timeline and the drug's adoption rate in the oncology segment, as it expands the company's high-margin specialty medicine portfolio.